Autopsy report · NCT02611128

Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia

“temporarily closed to enrollment due to COVID”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Suspended: paused, and may or may not restart.
• 65 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

University of Virginia

Sponsor type

University, hospital or other

Conditions

Polycystic Ovary Syndrome; Hyperandrogenism; Puberty

Interventions

Phenotype/genotype assessment

Participants

65 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Effects of rTMS on Human Brain Activity
  “Never started enrollment due to COVID-19 closures” (82% match in meaning)
• EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
  “No enrollment due to COVID” (79% match in meaning)
• Study of the Loss of AV Synchrony at Maximum Exercise
  “No Enrollments after COVID” (79% match in meaning)
• A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
  “Closed due to historically slow enrollment compounded by the COVID-19 pandemic.” (79% match in meaning)
• Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
  “Enrollment halted prematurely due to the Covid-19 pandemic” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.